1283 related articles for article (PubMed ID: 26075522)
1. Catalytic in vivo protein knockdown by small-molecule PROTACs.
Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
[TBL] [Abstract][Full Text] [Related]
2. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
3.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
4. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I; Wang H; Caldwell JJ; Chopra R
Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
7. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
8. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
9. A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
Shanmugasundaram K; Shao P; Chen H; Campos B; McHardy SF; Luo T; Rao H
J Biol Chem; 2019 Oct; 294(41):15172-15175. PubMed ID: 31511327
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
11. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
13. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
Cyrus K; Wehenkel M; Choi EY; Lee H; Swanson H; Kim KB
ChemMedChem; 2010 Jul; 5(7):979-85. PubMed ID: 20512796
[TBL] [Abstract][Full Text] [Related]
14. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
Wang C; Zhang Y; Wang J; Xing D
Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
[TBL] [Abstract][Full Text] [Related]
15. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
16. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
[TBL] [Abstract][Full Text] [Related]
17. Protein degradation: Prime time for PROTACs.
Deshaies RJ
Nat Chem Biol; 2015 Sep; 11(9):634-5. PubMed ID: 26284668
[No Abstract] [Full Text] [Related]
18. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
Ohoka N; Shibata N; Hattori T; Naito M
Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
[TBL] [Abstract][Full Text] [Related]
19. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
Mares A; Miah AH; Smith IED; Rackham M; Thawani AR; Cryan J; Haile PA; Votta BJ; Beal AM; Capriotti C; Reilly MA; Fisher DT; Zinn N; Bantscheff M; MacDonald TT; Vossenkamper A; Dace P; Churcher I; Benowitz AB; Watt G; Denyer J; Scott-Stevens P; Harling JD
Commun Biol; 2020 Mar; 3(1):140. PubMed ID: 32198438
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
